Cost of illness of cystic fibrosis in Germany: Results from a large cystic fibrosis centre

PharmacoEconomics

Volumn 30, Issue 9, 2012, Pages 763-777

  Heimeshoff, Mareike ^a   Hollmeyer, Helge ^b   Schreyögg, Jonas ^a,c   Tiemann, Oliver ^a,c   Staab, Doris ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cost of illness; Cystic fibrosis; Healthcare expenditure

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; COLISTIN; DORNASE ALFA; FLUTICASONE PROPIONATE PLUS SALMETEROL; ITRACONAZOLE; PANCREATIN; PANCRELIPASE; PANTOPRAZOLE; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CONTROLLED STUDY; COST OF ILLNESS; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG COST; EXPIRATORY RESERVE VOLUME; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INFANT; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PHARMACY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AMBULATORY CARE; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; GERMANY; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; YOUNG ADULT;

EID: 84865042017     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11588870-000000000-00000     Document Type: Article

References (37)

1. Cystic Fibrosis Foundation. Patient registry report [online]. Available from URL: Http://www.cff.org/LivingWithCF/ CareCenterNetwork/PatientRegistry/ [Accessed 2012 April 19]
2. Assael BM, Castellani C, Ocampo MB, et al. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol 2002 Sep; 156 (5): 397-401 (Pubitemid 34976977)
3. Horvais V, Touzet S, Bourdy S, et al. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int J Technol Assess Health Care 2006; 22 (4): 525-531 (Pubitemid 44622975)
4. Dodge JA, Morison S, Lewis PA, et al. Incidence, population and survival of cystic fibrosis in the UK, 1968-95. Arch Dis Child 1997 Dec; 77 (6): 493-496 (Pubitemid 28016366)
5. Mukoviszidose e.V. Annual report 2008/09 [in German;online]. Available from URL: Http://muko.info/fileadmin/ Dokumentenablage/Wer-wir-sind/ Publikationen/Jahresbe richt-08-09.pdf [Accessed 2010 Oct 05]
6. Krauth C, Jalivand N, Welte T, et al. Cystic fibrosis: Cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003; 21 (14): 1001-1024 (Pubitemid 37255455)
7. Cystic Fibrosis Foundation. About cystic fibrosis: What you need to know [online]. Available from URL: Http://www. cff.org/AboutCF/ [Accessed 2010 Mar 18]
8. Stern M, Sens B, Wiedemann B, et al., editors. Qualitätssicherung mukoviszidose: Überblick über Den gesundheitszustand der patienten in Deutschland 2005. Hanover: Zentrum für Qualität und Management im Gesundheitswesen and Mukoviszidose e.V., 2005
9. Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003 Jun; 2 (2): 84-90 (Pubitemid 36814095)
10. Schreyögg J, Hollmeyer H, Bluemel M, et al. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006; 24 (10): 999-1009 (Pubitemid 44497471)
11. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: A regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999 Oct; 19 (10): 1159-1166 (Pubitemid 29455937)
12. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009 Oct; 44 (10): 989-996
13. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 2009 Jul; 10 (4): 357-359
14. Zentner A, Velasco-Garrido M, Busse R. Methods of comparative evaluation for pharmaceuticals [in German]. 13th rev. ed. Berlin: German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information, 2005
15. Graf von der Schulenburg JM, Greiner W, Klusen N, et al. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. Value Health 2008 Jul-Aug; 11 (4): 539-544 (Pubitemid 352032814)
16. DeWitt EM, Grussemeyer CA, Friedman JY, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: Analysis of data collected alongsiDe a 48-week multicenter clinical trial. Value Health 2012; 15 (2): 277-283
17. Eidt-Koch D, Mittendorf T, Wagner T, et al. Evaluation von kosten der ambulanten behandlung bei mukoviszidose in Deutschland: Übersicht über die ergebnisse einer prospektiven studie. Med Klin 2009 Jul; 104 (7): 529-535
18. Eidt-Koch D, Wagner TOF, Mittendorf T, et al. Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany. Pediatr Pulm 2011; 46: 278-285
19. Clement FM, Ghali W, Donaldson C, et al. The impact of using different costing methods on the results of an economic evaluation of cardiac care: Micro-costing vs grosscosting approaches. J Health Econ 2009 Apr; 18 (4): 377-388
20. Raftery J. Costing in economic evaluations. BMJ 2000 Jun; 320: 1597
21. Robson M, Abbot J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992 Sep; 47 (9): 684-689
22. Wildhagen MF, Verheij JB, Verzikl JG, et al. Cost of care of patients with cystic fibrosis in the Netherlands in 1990-1 [published erratum appears in Thorax 1997; 52 (2): 204]. Thorax 1996 Mar; 51 (3): 298-301 (Pubitemid 26088554)
23. Rote Liste Service GmbH. Rote liste 2004. Frankfurt: Rote Liste, 2004
24. Stern M, Wiedemann B, Wenzlaff P, et al. From registry to quality management: The German cystic fibrosis quality assessment project 1995-2006. Eur Respir J 2008 Jan; 31 (1): 29-35
25. Cystic Fibrosis Trust. UK CF registry: Annual data report 2008 [online]. Available from URL: Http://www.cftrust. org.uk/aboutcf/publications/ cfregistryreports/UK-CF-Reg istry-Annual-Data-Report-2008.pdf [Accessed 2010 Sep 20]
26. Federal Statistical Office of Germany. Earnings and labour costs: Results for Germany [in German; online]. Available from URL https://www.destatis.de/DE/ Publikationen/ Thematisch/VerdiensteArbeitskosten/Arbeitskosten/Arbeits kostenBund2163201089004.pdf?-blob=publicationFile [Accessed 2012 April 19]
27. STATA [computer program]. Version 10. College Station (TX): Statacorp, 2007
28. Federal Statistical Office of Germany. Report browser for hospital data [in German; online]. Available from URL https://www.destatis.de/DE/ Publikationen/Thematisch/Ges undheit/AlteAusgaben/ KostennachweisKrankenhaeuserAlt. html?nn=72108 [Accessed 2012 April 19]
29. @RISK [computer program]. Version 5.5. Ithaca (NY): PalisaDe Corporation, 2009
30. Brouwer WB, Koopmanschap MA. The friction-cost method: Replacement for nothing and leisure for free? Pharmacoeconomics 2005; 23 (2): 105-111 (Pubitemid 40460650)
31. Schreyögg J, Tiemann O, Busse R. Cost accounting to determine prices: How well do prices reflect costs in the German DRG-system? Health Care Manag Sci 2006 Aug; 9 (3): 269-280
32. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999 Jun; 103: E72
33. Ireys HT, Anderson GF, Shaffer TJ, et al. Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid Program, fiscal year 1993. Pediatrics 1997 Jun; 100 (2): 197-204 (Pubitemid 27328196)
34. Simoens S. International comparison of generic medicine prices. Curr Med Res Opin 2007 Nov; 23 (11): 2647-2654 (Pubitemid 350146403)
35. Garattini L, Motterlinia N, Cornagoa D. Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. Health Policy 2008 Mar; 85 (3): 305-313 (Pubitemid 351179534)
36. Eidt-Koch D, Wagner T, Mittendorf T, et al. Outpatient medication costs of patients with cystic fibrosis in Germany. Appl Health Econ Health Policy 2010 Mar; 8 (2): 111-118
37. Braccini G, Festini F, Boni V, et al. The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Chemother. 2009 Apr; 21 (2): 188-192